Activity of BET-proteolysis targeting chimeric (PROTAC) compounds in triple negative breast cancer

Overview of attention for article published in Journal of Experimental & Clinical Cancer Research, August 2019

Altmetric Badge

About this Attention Score

In the top 5% of all research outputs scored by Altmetric
Among the highest-scoring outputs from this source (#17 of 2,429)
High Attention Score compared to outputs of the same age (96th percentile)
High Attention Score compared to outputs of the same age and source (98th percentile)

Mentioned by

news: 10 news outlets
twitter: 8 X users

facebook: 2 Facebook pages

Citations

dimensions_citation: 67 Dimensions

Readers on

mendeley: 112 Mendeley

Summary News X Facebook Dimensions citations

So far, Altmetric has seen 9 X posts from 8 X users, with an upper bound of 14,552 followers.

RT @EvaGalanMoya: ✅Our last paper is already online! Thanks to my PhD student, Mar Noblejas, & the rest of the team for your hard work 🍾🧬…

09 Dec 2019

Reply Repost Favourite

Un estudio realizado por los grupos de Atanasio Pandiella, del Centro de Investigación del Cáncer de Salamanca, y Alberto Ocaña, de la U.Castilla-La Mancha, demuestra la eficacia antitumoral de los fármacos BET-PROTAC. Publicado en https://t.co/eS8UNDzyhp

04 Oct 2019

Reply Repost Favourite

04 Oct 2019

Reply Repost Favourite

RT @EvaGalanMoya: ✅Our last paper is already online! Thanks to my PhD student, Mar Noblejas, & the rest of the team for your hard work 🍾🧬…

14 Sep 2019

Reply Repost Favourite

This page shows the most recent X posts that mention this research output.

Click here to find out how to access more activity, including 5 additional X posts.